Letter to the Editor: In Response to Hematology...Literally and Seriously
Dr. Rosenblum responds to The Hematologist Editor-in-Chief's commentary in the Year's Best issue.
A New Phase II Agent Holds Promise for First FDA Approved Therapy for Treatment of Acute Vaso-Occlusive Pain Events in SCD
Dr. DeBaun evaluates a new agent for the prevention of vaso-occlusive pain episodes in sickle cell disease that holds promise for first FDA approval since hydroxyurea.
Insightful critiques and informed commentary of important ongoing clinical trials
Drs. Raetz and Kovacsovics cover a trial meant to develop a precision medicine approach for the treatment of AML.
Dr. Moss covers a study that compares the PD-1 inhibitor pembrolizumab with brentuximab vedotin in subjects with relapsed or refractory classical HL.
Dr. Garcia discusses a study that tests a new therapeutic approach with antifibrinolytic agents to chemotherapy-associated thrombocytopenia.
Dr. Abdel-Wahab and Dr. Taylor cover a study that measures the safety of combination ABT-199 and hypomethylating agents in older adults with acute myelogenous leukemia (AML), who are treatment-naive and not eligible for standard induction therapy.
Dr. Cuker and Dr. George discuss a study that evaluates the safety, tolerability, and pharmacokinetics of SPK-9001 in subjects with hemophilia B.
Dr. Keel talks about a study that compares risks and benefits of alloHCT in older patients with higher-risk myelodysplastic syndromes.
Dr. Raje and Dr. Yee discuss a study that looks at the use of pembrolizumab in combination with lenalidomide or pomalidomide to treat multiple myeloma as a form of checkpoint inhibition, a new important tool in cancer treatment.
Dr. Stimpson and Dr. DeBaun look at a trial that evaluates research for HCT in severe sickle cell disease using HLA-identical siblings and unrelated donors for HCT compared with standard care due to the absence of a suitable donor.
Dr. Raetz and Dr. Loh cover a new study in pediatric ALL that tests the contribution of ruxolitinib to traditional chemotherapy for newly diagnosed, genetically defined subsets of patients who are known to have poor outcomes with standard therapy.
Dr. Coetzer discusses the N-PhenoGENICS trial and calls for new research to answer questions about secondary effects of chemotherapy in children.
March-April 2017Volume 14, Issue 2
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology